Low-dose steroid to prevent side effects from tebentafusp
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This study tests whether a low dose of a steroid called dexamethasone can help prevent a side effect (cytokine release syndrome) that often happens when you first receive the cancer drug tebentafusp. It is for people with advanced uveal melanoma who are starting tebentafusp as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of eye cancer called uveal melanoma that has spread to other parts of the body (advanced).
- You must have a specific genetic marker (HLA-A*02:01) that your doctor can check with a blood test.
- You must be about to start your first systemic treatment for advanced uveal melanoma with a drug called tebentafusp (Kimmtrak).
- If you can become pregnant or cause a pregnancy, you must agree to use effective birth control during treatment and for 6 months after the last dose.
- You cannot have used steroid medicines (such as prednisone or hydrocortisone) within the last 3 weeks before joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tebentafusp and roginolisib, for people with uveal melanoma that has spread or can't be removed. It aims to improve how long the immune system stays active against the cancer.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
This trial provides access to tebentafusp, a treatment for advanced melanoma of the eye that cannot be removed by surgery. It may help control the disease.
Hear when a new Uveal Melanoma, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.